Cargando…

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

INTRODUCTION: Clinical resistance is a major factor limiting benefits to endocrine therapy. Causes of resistance may be diverse and the mechanism of resistance in individual breast cancers is usually unknown. The present study illustrates how changes in the expression of proliferation and oestrogen-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, William R, Larionov, Alexey
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949641/ https://www.ncbi.nlm.nih.gov/pubmed/20646288 http://dx.doi.org/10.1186/bcr2611

Ejemplares similares

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
por: Wang, Shunde, et al.
Publicado: (2018)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Aromatase 2004, Edinburgh, UK, 6-8 September 2004
por: Miller, William R, et al.
Publicado: (2005)

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase
por: Hoeflich, Klaus P., et al.
Publicado: (2016)

Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
por: Balakrishnan, A, et al.
Publicado: (2011)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
por: Rezaei, Ako, et al.
Publicado: (2022)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
por: HOLE, STINE, et al.
Publicado: (2015)

Morphological and Functional Changes in Skin of Adult Male Rats Chronically Treated with Letrozole, a Nonsteroidal Inhibitor of Cytochrome P450 Aromatase
por: Misiakiewicz-Has, Kamila, et al.
Publicado: (2020)

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells
por: Abrhale, Tesfom, et al.
Publicado: (2011)

Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue
por: Alabiad, Mohamed Ali, et al.
Publicado: (2022)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
por: Garcia-Casado, Zaida, et al.
Publicado: (2010)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
por: Sun, Shengliang, et al.
Publicado: (2016)

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
por: Lisztwan, Joanna, et al.
Publicado: (2008)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization
por: Lee, Kyung-Hee, et al.
Publicado: (2014)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
por: De Luca, Michele, et al.
Publicado: (2022)

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours
por: Selli, Cigdem, et al.
Publicado: (2019)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b
por: Snell, Cameron E., et al.
Publicado: (2018)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

The significance of highlighting the oestrogen receptor low category in breast cancer
por: Poon, Ivan K., et al.
Publicado: (2020)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
por: Marina, Djordje, et al.
Publicado: (2022)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9km41c4c1rro7g4nf3s32l9pbu